The effects of magnesium and vitamin E co-supplementation on parameters of glucose homeostasis and lipid profiles in patients with gestational diabetes.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
magnesium plus vitamin E supplements | decrease | fasting plasma glucose | women with gestational diabetes (GDM) | β - 5.20 mg/dL | significantly lower | #1 |
magnesium plus vitamin E supplements | decrease | serum insulin levels | women with gestational diabetes (GDM) | β - 2.93 μIU/mL | significantly lower | #2 |
magnesium plus vitamin E supplements | decrease | homeostasis model of assessment-insulin resistance | women with gestational diabetes (GDM) | β - 0.78 | significantly lower | #3 |
magnesium plus vitamin E supplements | increase | quantitative insulin sensitivity check index | women with gestational diabetes (GDM) | β 0.01 | higher | #4 |
magnesium plus vitamin E supplementation | decrease | serum triglycerides | women with gestational diabetes (GDM) | β - 50.31 mg/dL | significant reduction in | #5 |
magnesium plus vitamin E supplementation | decrease | VLDL-cholesterol | women with gestational diabetes (GDM) | β - 10.06 mg/dL | significant reduction in | #6 |
magnesium plus vitamin E supplementation | decrease | total-cholesterol | women with gestational diabetes (GDM) | β - 26.10 mg/dL | significant reduction in | #7 |
magnesium plus vitamin E supplementation | decrease | LDL-cholesterol | women with gestational diabetes (GDM) | β - 15.20 mg/dL | significant reduction in | #8 |
magnesium plus vitamin E supplementation | decrease | total-/HDL-cholesterol ratio | women with gestational diabetes (GDM) | β - 0.46 | significant reduction in | #9 |
Magnesium and vitamin E co-supplementation | no change | HDL-cholesterol levels | women with gestational diabetes (GDM) | - | did not affect | #10 |
BACKGROUND: Magnesium and vitamin E are known to exert multiple beneficial effects, such as anti-glycemic and anti-lipidemic properties. The aim of this study was to determine the effects of magnesium and vitamin E co-supplementation on metabolic status of women with gestational diabetes (GDM). METHODS: This randomized, double-blinded, placebo-controlled trial was conducted among 60 subjects diagnosed with GDM, aged 18-40 years. Subjects were randomly allocated into two groups to receive 250 mg/day magnesium oxide plus 400 IU/day vitamin E supplements or placebo (n = 30 each group) for 6 weeks. Participants' blood samples were taken to determine their metabolic profiles. RESULTS: Subjects who received magnesium plus vitamin E supplements had significantly lower fasting plasma glucose (β - 5.20 mg/dL; 95% CI, - 7.88, - 2.52; P = 0.002), serum insulin levels (β - 2.93 μIU/mL; 95% CI, - 5.68, - 0.18; P = 0.02) and homeostasis model of assessment-insulin resistance (β - 0.78; 95% CI, - 1.42, - 0.14; P = 0.01), and higher quantitative insulin sensitivity check index (β 0.01; 95% CI, 0.005, 0.02; P = 0.002) compared with placebo. In addition, magnesium plus vitamin E supplementation resulted in a significant reduction in serum triglycerides (β - 50.31 mg/dL; 95% CI, - 67.58, - 33.04; P < 0.001), VLDL- (β - 10.06 mg/dL; 95% CI, - 13.51, - 6.60; P < 0.001), total- (β - 26.10 mg/dL; 95% CI, - 41.88, - 10.33; P = 0.004), LDL- (β - 15.20 mg/dL; 95% CI, - 29.50, - 0.91; P = 0.03) and total-/HDL-cholesterol ratio (β - 0.46; 95% CI, - 0.72, - 0.19; P < 0.001) compared with placebo. Magnesium and vitamin E co-supplementation did not affect HDL-cholesterol levels. CONCLUSIONS: Overall, magnesium and vitamin E co-supplementation for 6 weeks in women with GDM significantly improved glycemic control and lipid profiles, except for HDL-cholesterol levels. CLINICAL TRIAL REGISTRATION NUMBER: http://www.irct.ir : IRCT20170513033941N24.